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The universal burden of pneumococcal disease is high. As pneumococcal capsular antigens
induce serotype specific antibodies, both the available vaccines (polysaccharide and polysac-
charide conjugated) are able to produce serological response. However, there is reasonable
skepticism about the effectiveness and efficacy of the 23-valent polysaccharide vaccine, espe-
cially in the elderly and in immunocompromised adults. Results from numerous studies are
conflicting but the more recent data suggest that polysaccharide vaccine raises inadequate
protection against non-bacteremic pneumonia, while the benefit against invasive pneumo-
coccal disease in high-risk population is uncertain. On the contrary, conjugate vaccine, -orig-
inally indicated only for infants and young children- appears to be highly effective but it does
not cover the tremendous diversity of pneumococcal serotypes being able to cause disease in
adults. Despite this, there is growing evidence that conjugate vaccines, due to their superior
immunogenicity, could also be offered for adult vaccination, but still there are certain issues
that warrant further investigation.
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Streptococcus pneumoniae (pneumococcus) is a Gram-
positive diplococcus responsible for a spectrum of non-
invasive (mucosal) infections such as paranasal sinusitis,
otitis media and lobar pneumonia as well as invasive
diseases, including meningitis, bacteremia, bacteremic
pneumonia and/or empyema. It is widely accepted that
S. pneumoniae is the most commonly identified causative
organism in cases of community-acquired pneumonia (CAP)
in both ambulatory and hospitalized patients worldwide.
S. pneumoniae is a major source of morbidity and
mortality, particularly in the very young and in the elderly.
In the United States, approximately 500,000 cases of
pneumonia, 50,000 episodes of bacteremia and 3000 cases
of bacterial meningitis are attributed to S. pneumoniae
each year, with a case-fatality rate of 5e7%, 20% and 30%
respectively.1 In Europe, the incidence of CAP due to S.
pneumoniae appears to be higher than in other conti-
nents.2 Globally, pneumococcal disease is responsible for
an estimated 1.6 million deaths yearly and is the leading
cause of death from a vaccine-preventable disease in
children younger than 5 years of age.3,4 Infections caused
by S pneumoniae are also responsible for substantial
morbidity and mortality in adults with medical co-
morbidities or in those older than 65 years of age, who are
considered to be at increased risk for invasive pneumo-
coccal disease.5
Pneumococci are grouped into many serotypes (w91) on
the basis of their chemically and serologically distinct
capsular polysaccharides. Certain serotypes are much more
likely than others to be associated with clinically apparent
infections, to cause severe invasive infections and to
acquire resistance to one or more classes of antibacterial
agents.6 Proteins or enzymes on the surface of S. pneu-
moniae are important in pathogenesis of the disease
because they neutralize innate and adaptive host defense
mechanisms, thus enabling bacterial adhesins to promote
attachment of pathogen to respiratory epithelium.7 They
also facilitate colonization (i.e. nasopharynx), adherence
and host invasion. Progression from colonization to invasivedisease is dependent on interplay between virulence and
host defense.
Licensed pneumococcal vaccines
Due to large serotype diversity in pneumococcus, vaccines
that induce antibody responses against multiple capsular
antigens have had to be developed. The capsular poly-
saccharides of 23 serotypes (including the 6 that cause the
most invasive pneumococcal infections) comprise non-
conjugated pneumococcal polysaccharide vaccine (PPV),
which was licensed for adults in 1983. The vaccine covers
85e90% of serotypes responsible for invasive disease.1
There are two 23-valent pneumococcal vaccines (PPV23):
one that is used in the United States, Europe, and else-
where (Pneumovax 23) and another that is used in Europe
and Canada (Pneumo 23). The 0.5 ml dose of the vaccine
contains 25 mg of polysaccharide for each of the 23 included
serotypes in isotonic saline solution with 0.25% phenol as
a preservative. Pneumococcal capsular polysaccharide are
highly antigenic and therefore are able to induce serotype-
specific antibodies that enhance opsonization, phagocytosis
and killing by host immune response.8 A twofold or greater
increase in serotype-specific antibody develops within
three weeks in 80% or more of healthy young adults.1 Non-
conjugated pneumococcal polysaccharide vaccines activate
B-cells but elicit T-cell independent immune responses. As
a result, they do not elicit protective immune responses in
children aged less than approximately 2 years, they do not
induce immune memory and they devoid of booster effect.
In addition, polysaccharide vaccines do not induce mucosal
immunity and thus they have little or no impact on naso-
pharyngeal carriage.9e11
Polysaccharide vaccines are widely recommended for
use in adults who are at the highest risk of invasive pneu-
mococcal disease including individuals with a history of
chronic lung disease, heart failure, chronic renal failure
(including nephrotic syndrome), chronic liver disease
(including alcohol dependence and cirrhosis), diabetes
mellitus, asplenia/sickle cell disease, immunocompromised
individuals, such as those with HIV/AIDS or blood borne
1778 G.G. Pitsiou, I.P. Kioumisdyscrasias, patients with cochlear implants or chronic
cerebrospinal fluid leak, residents of nursing homes and
other long-term care facilities and all individuals older than
65 years. PPV23 is now also recommended for all asthmatics
18 years and older, and all individuals who smoke, irre-
spective of whether or not they have any coexisting risk
factors12 (Table 1).
Pneumococcal conjugate vaccines (PCVs), in which each
of the selected bacterial capsular polysaccharides is
coupled with a protein carrier molecule, have been a major
advance in the prevention of invasive pneumococcal
disease.13 The 7-valent PCV (PCV7, Prevnar/Prevenar)
employs an inactivated diphtheria CRM197 toxoid as the
carrier protein for all seven serotypes which helps improve
its immunogenicity. This vaccine was first licensed in the
USA in 2000 and subsequently has become available in
approximately 90 countries worldwide. In contrast to the
23-valent non-conjugated vaccine, the conjugated vaccines
activate B- and T-cell leading to immune memory. They
elicit strong adaptive and booster response. As a result,
they are immunogenic in infants under two years of age. In
addition, PCV 7 elicits mucosal immune responses in
immunized hosts most probably due to induction of IgA
antibodies. Mucosal immunity enables asymptomatic
carriers to eradicate colonizing pneumococci of vaccine
serotypes.14 Since 2006, PCV is recommended in routine
immunization schedules for children of this age, with
prioritization of their introduction in countries with high
child mortality rates and/or high rates of HIV infection.15
Pneumococcal conjugate vaccines that contain three
(PCV10, Synflorix) or six serotypes (PCV13, Prevnar 13/
Prevenar 13) in addition to those in the 7-valent PCV have
recently become available for use in infants and young
children in some countries.16
23-Valent polysaccharide vaccine
The safety of PPV23 is well documented. Local reactions,
usually mild and self limited, occur in 30%e50% of the
patients. Fever or myalgias occur in about 1% of the
patients. Serious adverse events are rare.17 There is about
a 3-fold increase in local reactions with revaccination, but
no increase in systemic or serious reactions is noted.17,18
Even though the vaccine is safe, immunization rates
remain low, ranging from 12.6% to 36.5% for at risk people inTable 1 PPV23 Vaccination: Summary of indications.12
Persons at risk for pneumococcal infection
Individuals older than 65 years
History of chronic disease
Immunocompromised individuals (HIV/AIDS or blood
borne dyscrasias)
Patients with cochlear implants or chronic cerebrospinal
fluid leak
Residents of nursing homes and other long-term
care facilities
Asthmatics 18 years and older
SmokersEurope.19 A wide range of factors, including demographic,
comorbidity, quality of life, social support and lifestyle have
been associated with pneumococcal vaccination status
among older adults with clinically diagnosed CAP.20
PPV may provide suboptimal protection of older adults
because antibody responses or even functional activity, as
measured by the elicitation of opsonophagocytic antibodies
after vaccination may be found lower in elderly for
a number of evaluated serotypes.21e23 It is suggested that
non-response to specific serotypes is the likely cause for
vaccination failure in the elderly; hence 23-valent pneu-
mococcal vaccine should be regarded as 23 different
vaccines.24 Furthermore, immune responses are typically
lower and less robust in individuals with co-morbidities
including cirrhosis, chronic obstructive pulmonary disease,
diabetes mellitus or immune-mediated inflammatory
diseases.1,25,26 In the population of COPD patients, clinical
and laboratory studies have suggested that the currently
approved vaccine is less effective than in healthier patients
and to date no randomized-controlled trial of pneumo-
coccal vaccination for COPD patients has demonstrated any
beneficial effect.25 Nevertheless, the administration of
systemic steroids does not influence the antibodies
response in these patients.27 Immunocompromised
patients, such as human immunodeficiency virus (HIV)-
infected persons, alcoholics and diabetics are less likely to
respond to vaccination with pneumococcal poly-
saccharides; in these patients antibody responses may be
markedly diminished or even absent.28,29Revaccination- duration of immunity
Vaccination with PPV23 produces a peak rise of the levels of
antibodies which thereafter progressively fall, during the
following 5 to 10 years. This fall is more prominent in some
populations. However, it should be underlined that it is not
known what level of antibody is protective. Current
recommendations for revaccination support 1-time revac-
cination after 5 years in persons with functional or
anatomic asplenia, in immunocompromised conditions and
also in individuals older than 65 who were first immunized
before the age of 65 12 (Table 2). Multiple revaccinations
are not recommended because of insufficient data
regarding clinical benefit, particularly the degree and
duration of protection and safety.12 Actually, the benefit of
revaccination remains uncertain since vaccination with
pneumococcal polysaccharide antigens may induce hypo-
responsiveness on rechallenge. Antibody response occurs
after a second dose, but it is less robust after the second
compared with the first dose.30,31 Thus, although revacci-
nation leads to an immunological response, administration
of a first dose of vaccine may blunt the immune response to
subsequent doses.32 This may potentially be associated
with a corresponding decrease in the magnitude of clinical
protection provided by revaccination. These observations
were challenged by a recent publication which concluded
that repeat revaccination with PPV was immunogenic to
Alaskan adults aged 55e74 years.33 Notably, there is some
evidence that 7-valent pneumococcal conjugate revacci-
nation of seniors previously vaccinated with PPV23 provides
a stronger immune response.34
Table 2 PPV23 Revaccination: Summary of indications.12
Revaccination: 1-time revaccination after 5 years
Persons with functional or anatomic asplenia
Immunocompromised persons
Individuals older than 65 if vaccinated  5 years
previously when < 65 years old
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Although the PPV has been widely introduced into vacci-
nation programs for elderly people and high-risk pop-
ulations, the degree of protection afforded remains
a controversial issue. A number of caseecontrol and cohort
studies provide support for the effectiveness of PPV23 in
reducing the risk of invasive disease in immunocompetent
older adults.29,35e42 In the largest case-control study of
PPV23 effectiveness, a total of 983 cases of invasive
pneumococcal disease were evaluated; the study identified
an efficacy of 47% for all patients and 53% for immuno-
competent adults regardless of the serotype causing the
illness, but only 21% for the immunocompromised patients
when they were infected by a strain represented in the
vaccine.35 These results support the use of pneumococcal
polysaccharide vaccine to prevent bacteremic disease in
adults aged 65 years or over.43 Nevertheless, a decrease in
vaccine effectiveness both with age and with time since
vaccination was demonstrated in the aforementioned
study.35 Finally, the protective value of polysaccharide
vaccine in invasive pneumococcal disease was recently
reviewed by a synthesis of 9 different meta-analyses,
showing substantial efficacy in all adult population (83%e
63%) but not in high-risk population (0%e42%) for all sero-
types.44 The same review concluded that the effect of the
PPV23 on mortality prevention from either invasive disease
or pneumonia, was very limited, if any.Efficacy against non-bacteremic pneumococcal
pneumonia
Both influenza vaccine and PPV have been reported as
protective factors against CAP.45,46 However, the protective
effect of PPV against pneumococcal pneumonia without
bacteremia is unclear.
In a prospective randomized study which included 1006
nursing home residents in Japan, PPV23 prevented pneu-
mococcal pneumonia and reduced mortality from pneu-
monia among nursing home residents the majority of whom
are very old and have co-morbidities.47 Also in hospitalized
patients with CAP, prior vaccination against pneumococcus
was associated with improved survival, decreased chance
of respiratory failure or other complications, and decreased
length of stay.48 Similarly, a Canadian 6-hospital-based
prospective observational study concluded that although
PPV23 possibly fails to prevent CAP, it could modify the
severity of the infection lowering mortality (as much as
40%) or ICU admission, thus suggesting the persistence of
the current adult pneumococcal vaccination guidelines.49On the contrary, an early randomized, double-blind,
placebo-controlled trial testing the efficacy of the 14-
valent PPV in 2295 high-risk patients failed to prove
protection against pneumonia or bronchitis.50 Furthermore,
in a retrospective study of a large population of 47,365
older adults, pneumococcal vaccination was associated
with a significant reduction in the risk of pneumococcal
bacteremia but did not alter the risk of outpatient pneu-
monia or of any case of community-acquired pneumonia.51
These results are consistent with those of four meta-
analyses of prospective randomized trials of PPVs, all of
which concluded that there is no evidence that the vaccine
is associated with a reduction in the risk of pneumonia from
any cause among older adults.52e55
According to a meta-analysis by Melegaro et al, PPV23
vaccine efficacy against invasive pneumococcal disease in
the general elderly population is 65% (95% CI: 0.49e0.92)
whereas it has a moderate effect in the high-risk elderly
with an efficacy of 20% (95% CI: 1.88e0.78). The vaccine
has little or no effects against pneumonia in the general
elderly (efficacy 16%) while in high-risk elderly individuals it
is only about 20% efficacious.56 Similarly, in a recent meta-
analysis which included 22 trials involving 101,507 partici-
pants, there is little evidence of vaccine protection among
elderly patients or adults with chronic illness for
presumptive pneumococcal pneumonia (RR 1.04, 95% CI
0.78e1.38), for all-cause pneumonia (RR 0.89, 95% CI
0.69e1.14) and for all-cause mortality also (RR 1.00, 95% CI
0.87e1.14).57
Cost-effectiveness
Despite the skepticism about the actual efficacy of the
PPV23, an analysis of the published literature identified 11
economic evaluations, all supporting the cost-effectiveness
of PPV23.58 However, most of these studies were conducted
before the introduction of 7-valent PCV into infant immu-
nization schedules. Since it is shown that age groups not
targeted to receive PCV7 have reduced rates of invasive
disease as a result of indirect protection (see text below),
this issue may warrant re-analysis.3 Moreover, the
outcomes of these studies depend on a variety of factors,
such as the characteristics of the populations, the end-
points, invasive pneumococcal disease incidence, case-
fatality and the applied vaccine efficacy. For example,
European and American studies supporting cost-
effectiveness of PPV23 accept the assumption that the
effectiveness of the vaccine for persons >65 years ranges
from 75% in the 1st year to 33% in the 6th year, a fact that is
highly debatable.59,60
Polysaccharide conjugate vaccines
Clinical efficacy of pneumococcal conjugate
vaccines
PCVs have been an important landmark in the global control
of pneumococcal disease. The routine use of the 7-valent
PCV has resulted not only in tremendous reduction of
invasive infection in children but also in decrease in rates of
pneumococcal disease in the elderly population, thus
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unvaccinated persons.61,62 Unlike the PPV23, the pneumo-
coccal conjugate vaccine is effective in reducing nasopha-
ryngeal carriage of serotypes included in the vaccine and
some types that are not included. Obviously, a diminution
of the carrier rate reduces the transmission to non-carriers
and the risk of subsequent disease. Because of this, the
vaccine induces what is referred to as “herd immunity,” i.e.
immunizing a proportion of the population in any commu-
nity reduces disease in unvaccinated individuals.63
Correspondingly, use of the PCV7 has led not only in
a rapid fall in pneumococcal disease rates among children
but also to a major decline in the prevalence of invasive
pneumococcal disease and a modest decrease in respiratory
tract infections in adult population.64 On the other hand,
rates of invasive disease due to some non-PCV serotypes
have somewhat increased, including rates of disease due to
serotypes included in PPV (especially 19A)65 and serotypes
not present in either vaccine (such as 23A). As a result, in
the United States during the era of widespread PCV7
vaccination, the annual incidence of disease among chil-
dren and elderly due to non-vaccine serotypes is
increasing.66 This is a point of particular concern because
an everlasting emerge of replacement strains renders the
formulation of conjugate vaccines a moving target.67 In
addition, a serotype-specific immune unresponsiveness to
PCV following invasive pneumococcal disease has been
observed.68
Interestingly, the introduction of the pediatric conju-
gate vaccine was associated with an overall decrease in
invasive disease among HIV-infected adults, despite
increased disease caused by non-vaccine serotypes.69
Moreover, it has been shown that a 9-valent PCV was
quite effective in preventing pneumonias associated with
respiratory viruses, providing evidence that pneumococcus
has a major role in the development of such pneumonias
and that viruses contribute to the pathogenesis of bacterial
pneumonia.70Experience in adults
The remarkable success of protein-conjugate vaccines
among young children has renewed interest in the possible
use of these vaccines in older adults. Possible advantages of
PCVs in elderly adults may include higher levels of protec-
tion against the vaccine serotypes after vaccination and the
ability to prolong the duration of protection by use of
repeated vaccinations over time.71 Preliminary studies in
healthy adults older than age 70 years have shown that
PCV7 induces greater functional antibody activity at one
month post vaccination than does PPV23, although this
response is reduced in those who have been previously
vaccinated.72,34 In this population the 1.0-ml dose of PCV7
induced a greater immune response than the pediatric 0.5-
ml dose (containing 2 mg of capsular polysaccharide from
serotypes 4, 9 V, 14, 18C, 19F, and 23F and 4 mg of serotype
6B). No additional benefit was observed with a 2.0-ml
dose.34 In patients with COPD, PCV7, when given at twice
the dose recommended for children, induced a superior
immune response at one month post vaccination compared
with PPV23. In the same study, both older age and priorPPV23 vaccination were shown to impair PCV7 responsive-
ness.73 Taken together, these studies suggest that although
protein-conjugate vaccines may induce superior immune
responses compared to the polysaccharide vaccine, the
optimal dose in adults is uncertain and higher doses may be
needed in those previously vaccinated with PPV23.
Furthermore, despite the greater immunogenicity of PCV7,
it is not clear that the vaccine will prevent acute exacer-
bations of COPD.73
Another important limitation of PCVs is the low serotype
coverage. The 13-valent PCV (PCV13), which offers greater
serotype coverage than PCV7, is currently being evaluated
in clinical trials in healthy adults.74,75 CAPITA (Community
Acquired Pneumonia Immunization Trial in Adults) is
a randomized, placebo-controlled trial, with a 1:1 random
allocation planned to establish the efficacy of the 13-valent
PCV vaccine in the prevention of a first episode of vaccine
serotype specific pneumococcal pneumonia in 85,000
community-dwelling adult persons aged 65 years and
older.76 The study will take place in the Netherlands where
a large group of adults 65 years, naive to PPV23, is
available which makes it possible to conduct a large
placebo-controlled efficacy study in this age group.
Finally, as there is accumulating evidence that incidence
of pneumococcal disease in adults in the United States and
Europe is decreasing and given that cost of PCV13 is
substantially higher than PPV23, the cost-effectiveness of
possible PCV widespread adult vaccination is questionable.
Besides, higher cost could be prohibitive for developing
countries.67 On the other hand, the favorable outcome of
PCV vaccination in HIV-infected adults in Africa, shown in
a recent randomized clinical efficacy trial, supports PCV as
an additional intervention for improving care in that
patient population.77Conclusions
As pneumococcal infections cause a large burden of disease
worldwide, the control of this disease with an efficacious
vaccine is highly desirable. Effective prevention of pneu-
mococcal CAP and invasive pneumococcal disease through
influenza or pneumococcal vaccination has been a high-
priority issue for health policy makers worldwide. An
overall assessment of the published studies possibly derives
the following conclusions:
- PPV vaccination appears cost effective for the elderly
although the vaccine might only be effective in pre-
venting invasive disease.
- Due to limited immunogenicity in those with underlying
high-risk conditions, PPV23 provides incomplete
protection, especially in the immunocompromised and
elderly patients.
- PPV does not appear to be particularly effective in
preventing pneumonia, even in populations for whom
the vaccine is currently recommended. It is also
uncertain whether PPV could have any modifying effect
on the severity of the disease or the mortality rate.
These underscore the critical need to evaluate other
vaccine formulations for the prevention of non-invasive
pneumococcal infections in adults and require the
Pneumococcal vaccination in adults 1781development of more effective pneumococcal vacci-
nation strategies.78
- The introduction of PCV as a routine vaccination for
infants not only reduced invasive infection in children
but had an indirect protective effect on unvaccinated
persons. Newer formulation of PCV including additional
13 serotypes could prove to be good future option.
However, its use in adult population needs to be thor-
oughly evaluated.
- The phenomenon of serotype replacement in which
decreases in disease due to vaccine-type S. pneumo-
niae are counterbalanced by increases in disease due to
non-vaccine serotypes, may ultimately limit the
protection offered by any serotype-specific vaccine.71
New options for future vaccine development include
a number of protein-based pneumococcal vaccine candi-
dates which offer the potential advantage of serotype-
independent protection as well as the increasing avail-
ability of adjuvants.78,79
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